Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year ...

Myriad Genetics (NASDAQ:MYGN) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...

He earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley. About Myriad Genetics Myriad Genetics is a ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...

He earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley. Myriad Genetics is a leading molecular ...